Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Marino Garcia will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 pm EST and will hold one-on-one investor meetings.
A webcast of the presentation will be available in the company’s Investors section under “News and Events.” The announcement highlights investor access opportunities but does not provide financial or clinical data in this release.
Positive
- None.
Negative
- None.
News Market Reaction – DNTH
In the Jan 5 session, DNTH declined 7.03%, reflecting a notable negative market reaction. Argus tracked a trough of -3.0% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Clinical trial start | Positive | -2.6% | Initiation and first dosing in Phase 1 LBL-047 (DNTH212) trial. |
| Nov 24 | Investor conference | Neutral | +5.4% | Participation in Evercore healthcare conference with fireside chat and meetings. |
| Nov 05 | Earnings and update | Positive | +1.6% | Q3 2025 results and positive updates on claseprubart and DNTH212. |
| Nov 04 | Multiple conferences | Neutral | -2.4% | Announcement of participation in four investor conferences in November. |
| Oct 29 | Clinical data update | Positive | +0.5% | New Phase 2 MaGic and preclinical claseprubart data at AANEM meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most prior news events showed price moves generally aligning with the underlying news tone, with one notable divergence on positive clinical-trial progress.
Over the past few months, Dianthus reported positive clinical and business developments, including new claseprubart Phase 2 data on Oct 29, 2025 and Q3 2025 results with a strengthened cash position on Nov 5, 2025. The company also expanded visibility through multiple investor conferences in November and announced initiation of a Phase 1 trial for DNTH212 on Dec 23, 2025. Today’s J.P. Morgan Healthcare Conference participation fits this pattern of active investor engagement alongside ongoing clinical advancement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the 44th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 p.m. EST and will host one-on-one meetings with investors.
A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
